Immunic, Inc. (IMUX), Tuesday announced the appointment of Michael Panzara, as Chief Medical Officer, succeeding Andreas Muehler, effective April 24, 2026.
In this new role, he will lead the company's development organization, including clinical development, medical affairs, and regulatory affairs, and will be a critical partner to the CEO and the Board of Directors in defining and driving the overall company strategy.
Panzara most recently served as Chief Medical Officer of Neurvati Neurosciences, Inc.
In light of his appointment, the Compensation Committee of Immunic's Board of Directors granted Panzara an initial equity option to purchase 300,000 shares of common stock of the company under the Immunic, Inc. 2026 Inducement Equity Compensation Plan.
In the pre-market hours, IMUX is trading at $9.70, down 2.81 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.